Clinical and demographic characteristics of our multicentre cohort of patients with SSc-ILD
| Clinical and demographic characteristics | 90 patients |
| Female, n (%) | 65 (72) |
| Age (years), mean±SD | 57.6±13.4 |
| Disease duration (years), mean±SD | 8.8±7.6 |
| Smokers, n (%) (active or former) | 18 (20) |
| Cutaneous subset | |
| Diffuse, n (%) | 40 (44.0) |
| Limited, n (%) | 41 (45) |
| Sine scleroderma, n (%) | 9 (10) |
| Autoantibodies | |
| Anti-topoisomerase I Ab, n (%) | 67 (74) |
| Anti-RNA polymerase III Ab, n (%) | 2 (2) |
| Anti-centromere Ab, n (%) | 5 (5) |
| Anti-U1-RNP Ab, n (%) | 6 (7) |
| Anti-Th/T0, n (%) | 2 (2) |
| Organ involvement | |
| GI involvement | 83 (92) |
| Myositis | 9 (10) |
| Myocarditis | 10 (11) |
| Scleroderma renal crisis | 0 (0) |
| Digital ulcer | 11 (12) |
| Pulmonary arterial hypertension | 1 (1) |
| Previous therapies | 84 patients |
| Mycophenolate mofetil, n (%) | 65 (77) |
| Methotrexate, n (%) | 8 (9) |
| Cyclophosphamide, n (%) | 31 (37) |
| Azathioprine, n (%) | 14 (17) |
| Tocilizumab, n (%) | 6 (7) |
| Rituximab, n (%) | 26 (31) |
| Concurrent therapies | 77 patients |
| Corticosteroids, n (%) | 71 (92) |
| Mycophenolate mofetil, n (%) | 63 (81) |
| Methotrexate, n (%) | 2 (3) |
| Cyclophosphamide, n (%) | 0 (0) |
| Azathioprine, n (%) | 2 (3) |
| Tocilizumab, n (%) | 5 (6) |
| Rituximab, n (%) | 18 (23) |
| Baseline HRCT | 89 patients |
| NSIP, n (%) | 61 (69) |
| UIP, n (%) | 28 (31) |
Ab, antibodies; GI, gastrointestinal; HRCT, high-resolution CT; ILD, interstitial lung disease; n, number; NSIP, non-specific interstitial pneumonia; SSc, systemic sclerosis; UIP, usual interstitial pneumonia.